Sunday 8 November 2026 Export IDXG’s income statement to Excel — free account

Interpace Biosciences, Inc.

IDXG

Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024.

Revenue: −1.09%
EPS: +104.1%
Free cash flow: −92.1%

Quarter to June 2026, against a year earlier

Operating cash flow growth 5 yrs

7.00 0.00 0.00%

Follow IDXG

Alert me

Market cap: —
P/E: 0.3×
Fwd P/E: —
Dividend yield: —
F-score: 5/9
Altman Z: −6.72
Beneish M: 2.07
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership —

Capital & Financial Ratios $m

Size

Market Cap —

Revenue ttm 36.14

Net income ttm 24.45

Free cash flow ttm 4.10

Net debt Q (2.69)

Valuation

P/E 0.26

Forward P/E —

Price / sales 1.07

Forward P/S Powerpack

Price / FCF 9.45

Price / book 1.67

Financial health

Current ratio Q 2.22

Debt / equity Q 0.00

Interest coverage Q 137.40

Growth

Revenue growth Q −1.09%

Operating income growth Q +168.59%

EPS, this year —

EPS, next year A —

Revenue, next year A —

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 90.80%

10-year low 10-year high

EV/Sales against its own 10 years 86.08%

10-year low 10-year high

EV/FCF against its own 10 years 90.55%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	1	3	3
Receivables	5	9	6	6
Inventory	—	—	—	—
Other	2	2	2	2
	10	12	10	11

	2023	2024	2025	Q'26
Payables	2	2	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	11	11	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	15.17%	3.63%	6.75%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	5.54%	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q4 FY22 Estimate −0.35 Actual −1.65

−5.24 −3.86 −2.47 −1.09 0.29

Q1 FY22 Beat +1.40

Q2 FY22 Miss −2.00

Q3 FY22 Miss −0.25

Q4 FY22 Miss −1.30

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q1 FY22	−4.00	−2.60	Beat by 1.40
Q2 FY22	−2.60	−4.60	Miss by 2.00
Q3 FY22	−1.25	−1.50	Miss by 0.25
Q4 FY22	−0.35	−1.65	Miss by 1.30

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.15	0.03	—	—	—
’25	0.30	(0.70)	0.15	4.09	4.45
’24	0.81	2.77	1.89	0.14	2.00
’23	0.40	0.20	(0.70)	2.34	2.24
’22	(2.65)	(4.65)	(16.75)	(1.85)	(25.90)
’21	(5.15)	(4.20)	(4.25)	(4.45)	(18.07)
’20	(11.60)	(6.80)	(7.70)	(10.05)	(36.60)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	9	9	—	—	—
’25	12	9	9	9	39
’24	10	12	12	12	47
’23	10	11	9	10	40
’22	8	7	8	8	32
’21	10	11	8	4	33
’20	9	5	8	10	32

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	1	1	2	2	6
’24	0	1	2	1	5
’23	1	0	1	1	4
’22	(1)	(3)	(3)	0	(8)
’21	(5)	(2)	(1)	(1)	(9)
’20	(7)	0	(6)	(2)	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	1	1	2	2	5
’24	0	1	2	1	4
’23	1	0	1	1	3
’22	(1)	(3)	(3)	0	(8)
’21	(5)	(2)	(1)	(1)	(9)
’20	(7)	0	(6)	(2)	(16)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	13	16	22	24	32	33	32	40	47	39	36		+12.8%	—	—	—	—
	Gross margin, %	49.25	53.71	53.43	34.40	33.10	56.78	57.26	62.58	63.77	62.31	63.75		+13.1 pt	Powerpack Interpace Biosciences, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(9)	(13)	(13)	(27)	(26)	(8)	(6)	2	7	4	4		n/m
	EBT margin, %	(65.51)	(82.61)	(58.01)	(110.16)	(80.71)	(23.38)	(18.33)	5.70	14.81	9.74	11.06		+75.3 pt
	Net income	(8)	(12)	(13)	(27)	(26)	(15)	(22)	2	7	25	24		n/m
Per share, $
Per share, $	Revenue	360.47	50.42	38.88	32.33	40.21	40.04	37.56	46.37	53.48	43.77	6.52		(20.9%)
	Earnings	(229.50)	(38.50)	(21.50)	(36.25)	(36.60)	(18.05)	(25.90)	2.26	7.10	27.75	26.83		n/m
	Cash flow	(209.56)	(48.41)	(15.40)	(25.30)	(17.35)	(10.54)	(9.07)	4.39	5.30	6.59	0.80		n/m
	Capex	0.00	(0.09)	(0.80)	(18.62)	(1.95)	(0.38)	(0.38)	(0.54)	(1.00)	(0.40)	(0.06)		n/m
	Free cash flow	(209.56)	(48.50)	(16.20)	(43.92)	(19.30)	(10.92)	(9.45)	3.84	4.30	6.19	0.74		n/m
	Book value	179.92	126.45	27.43	(5.98)	(36.09)	(51.29)	(74.41)	(64.33)	(2.53)	25.27	4.20		(19.6%)
	Shares, m	0	0	1	1	1	1	1	1	1	1	3		+42.6%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.43	1.90	0.22	0.26		0.5
	P/S	1.05	1.05	1.05	1.05	0.39	0.93	0.13	0.12	0.25	0.14	1.07		0.6
	P/B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.24	1.67		0.0
	EV/Sales	1.23	1.23	1.23	1.23	0.51	1.28	0.41	0.17	0.28	0.15	1.08		0.8
	EV/FCF	(1.57)	(1.57)	(1.57)	(1.57)	(1.12)	(4.70)	(1.64)	2.11	3.51	1.15	9.49		(0.7)
Cash, $m
Cash, $m	Operating cash flow	(8)	(15)	(9)	(19)	(14)	(9)	(8)	4	5	6	4		n/m
	Capex	—	0	0	(14)	(2)	0	0	0	(1)	0	0		+36.8%
	Free cash flow	(8)	(15)	(9)	(33)	(16)	(9)	(8)	3	4	5	4		n/m
Balance, $m
Balance, $m	Working capital	(12)	12	9	(1)	(4)	(4)	(2)	(1)	1	5	6		n/m
	Net debt	7	(15)	(6)	1	(3)	7	9	1	(1)	(3)	(3)		n/m
	Shareholders’ equity	7	40	15	(4)	(29)	(42)	(63)	(56)	(2)	22	23		+14.7%
Returns, %
Returns, %	ROA	(15.22)	(25.62)	(29.99)	(65.73)	(60.65)	(35.53)	(80.72)	13.43	44.70	101.07	104.29		+116.3 pt
	ROIC	(29.10)	(15.94)	(84.19)	0.00	0.00	0.00	0.00	0.00	0.00	12.85	12.67		+41.9 pt
	ROE	(85.16)	(52.66)	(45.93)	(495.47)	175.70	41.80	41.63	(3.29)	(21.60)	243.97	221.93		+329.1 pt
People
People	Employees	61	75	89	178	152	147	94	108	111	102	—		+5.9%
	Revenue/emp, $m	0.21	0.21	0.25	0.14	0.21	0.23	0.34	0.37	0.42	0.38	—		+6.5%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

No peers yet.

Pay and ownership Proxy statement filed 7 July 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	708.19k	708.19k	118.00
2024	703.79k	703.79k	260.00
2023	678.41k	608.07k	104.00

Ownership

Directors and executive officers, together less than 1%

Ampersand 50.00%

1315 Capital II, L.P. 34.00%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement